The approval by the FDA for the use of Risperdal in the treatment of schizophrenia and bipolar disorder in children is a momentous event. The decision was apparently made on the basis of a few very short term studies populated by a small number of subjects, a decision which is most uncharacteristic of the FDA. I have a number of acquaintances involved in drug development who have indicated to me that it is very difficult to find children available for any studies involving neuroleptics, let...